secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elanco Animal Health Inc (ELAN)
CIK:        0001739104
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001739104-26-000027
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elanco Q1 revenue +15% to $1.37B, raises FY2026 guidance across all metrics
---------------------------------------------------------------------------

- Q1 revenue $1.37B (+15% reported, +10% organic constant currency); adjusted EPS $0.40 vs $0.37 prior year.
- Full-year 2026 guidance raised: revenue $5,010-$5,085M, adj. EBITDA $975-$1,005M, adj. EPS $1.03-$1.09.
- Q2 2026 guidance: revenue $1,300-$1,325M, adj. EBITDA $240-$260M, adj. EPS $0.25-$0.28.
- Innovation revenue target raised to $1.2B; net leverage target improved to 3.0x-3.2x.
- Credelio Quattro and Zenrelia post strong share gains; closed AHV International acquisition Apr 30.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739104/000173910426000027/0001739104-26-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739104/000173910426000027/elan-20260506.htm
  HTML page:      https://secwatch.observer/filing/0001739104-26-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer